David Wild on Muck Rack

David Wild

Verified
Toronto
As seen in: Citeline, In Vivo, Apple Podcasts, CNN, The New York Times, Color Research & Application, HuffPost, Variety, Billboard, Elsevier, Quartz, Rolling Stone and
I cover the world of pharma and biotech for In Vivo @invivonow, a @Citeline publication. I also play in a Grateful Dead cover band. Please DM with story ideas.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

BIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exits

|
By Mandy Jackson Verified, Bridget Silverman Verified, David Wild Verified
| Scrip Verified
A Better Type Of Biotech M&A Cantor Fitzgerald biotechnology research analyst Josh Schimmer offered some thoughts on why the industry could continue to have a strengthening fundraising environment for at least two to five years during a June 25 discussion about venture capital mega-rounds at the BIO International Convention.
Open in Who Shared View Duplicates (2) Issue with article?

BIO Notebook: A Post-Mortem On CNPV

|
By Bridget Silverman Verified, Mandy Jackson Verified, David Wild Verified
| The Pink Sheet Verified
A Better Way To CNPV The confusing rollout of former FDA Commissioner Martin Makary’s Commissioner’s National Priority Voucher illustrates the value of the FDA’s usual deliberative process on a new program, former FDA officials agreed during a panel looking back at the Makary era. While the program has officially dropped the “Commissioner” from the name, all panelists still called it the CNPV, illustrating the close association with Makary.
Open in Who Shared View Duplicates (2) Issue with article?

BIO Notebook: MFN, Potential China Deals Ban Weigh Heavily On Dealmaking

|
By Mandy Jackson Verified, David Wild Verified, Bridget Silverman Verified
| Scrip Verified
Day 2 Of The BIO International Convention The BIO annual meeting continues with pharma execs reacting to potential legislation blocking deals with China, a look at how most favored nation pricing policies are affecting deal terms, NVIDIA's new agentic AI toolkit for life sciences, and FDA officials discuss hiring efforts.
Open in Who Shared View Duplicates (2) Issue with article?
See all 759 licensed articles (796 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified